Skip to content
Review

The Impact of β-Blocker Therapy on Peak VO2 in Heart Failure with Preserved Ejection Fraction: A Systematic Review and Meta-analysis.

Aug 2026 · American Journal of Cardiovascular Drugs · 0 citations · 23 references
Medicine

TL;DR

BB therapy was associated with lower objective peak VO2 without consistent effects on patient-reported outcomes or natriuretic peptides.

View source

Similar papers

Review Oct 2026

The effect of beta-blockers in heart failure with preserved ejection fraction and atrial fibrillation: systematic review and meta-analysis.

In patients with HFpEF and concomitant AF, beta-blocker therapy is associated with significant reductions in all-cause and cardiovascular mortality and a permissive clinical approach to beta-blocker use is supported, particularly for rate control in those with elevated heart rates.

Shahrukh Mohammed, Khubaib Mohammad Murtafa, Rohit Vondivillu Srinivasan et al. · 0 citations
#small language model Review Open access Sep 2026

Soluble ST2 dynamic changes predict the cardiorenal protective efficacy of arni in patients with heart failure with preserved ejection fraction: a meta-analysis

Background: Heart failure with preserved ejection fraction (HFpEF) accounts for approximately 50% of HF cases, predominantly affecting older adults with comorbidities such as hypertension, diabetes, and obesity. Despite the breakthrough provided by angiotensin receptor-neprilysin inhibitors (ARNI), approximately 30%...

Yong Il Ho, Zhi-Quan Wang, Jong-Suk Mun et al. · 0 citations
Review Open access Aug 2026

Beta-Blocker Discontinuation in Heart Failure with Preserved or Improved Ejection Fraction: A Systematic Review.

In HFpEF, beta-blocker discontinuation improved functional capacity and quality-of-life at 2 weeks compared with continuation with no clear effect on cognition, echocardiographic parameters or CV biomarkers, but findings on important long-term clinical outcomes was conflicting.

Wade Thompson, Nima Alaeiilkhchi, Lisa M. McCarthy et al. · 0 citations
Open access Sep 2026

Dissociation between heart rate reduction and left ventricular filling pressure in heart failure with preserved ejection fraction: a meta-analysis of ivabradine trials

Background: Heart rate (HR) reduction is commonly proposed to improve diastolic fi lling and reduce left ventricular (LV) fi lling pressure in heart failure with preserved ejection fraction (HFpEF). Ivabradine selectively lowers HR without direct myocardial effects, providing a mechanistic model to examine whether HR...

I. Wedharga, M. Hendri, M. Sanusi et al. · 0 citations
Open access Aug 2026

Heart Failure With Reduced Ejection Fraction and SGLT2 Inhibitors- Clinical Outcomes, Adverse Events, and Comorbidities Over Three Years: A Retrospective Cohort Study

SGLT2 inhibitor use in heart failure with reduced ejection fraction was associated with significantly improved long-term survival and a substantial reduction in heart failure and acute coronary syndrome hospitalizations, without increased risk of AKI or UTI.

Jonathan Zawadzki, Ronit Kar, G. Bailey et al. · 0 citations

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.